3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
40
Phase 2
34
Phase NA
15
Phase 1/2
13
Phase 3
8
Phase 2/3
1
Status
Unknown
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
13
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
9
Recurrence
6
Prostatic Neoplasms
6
Neoplasm Metastasis
6
Head and Neck Neoplasms
6
Carcinoma, Hepatocellular
6
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Squamous Cell
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Melanoma
4
Liver Neoplasms
4
Ovarian Neoplasms
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Hematologic Neoplasms
3
Fatigue
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Depression
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Rectal Neoplasms
2
Interventions
umbralisib
1
ublituximab
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Terminated
×
Lymphoma, B-Cell, Marginal Zone
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA